摘要
只有深入了解Treg细胞在抗肿瘤免疫中的作用和调节,并发现新的免疫靶点,新一代免疫治疗才能有效。这可以提高未来和新疗法的临床疗效,并减少由后者引起的不良反应。本文讨论了在肿瘤微环境(TME)中使用调节性T (Treg)细胞治疗肿瘤的策略。讨论了影响TME不稳定的因素以及预防未来免疫紊乱的相关治疗方法。据预测,PD-1抑制剂有风险,在治疗急性髓系白血病(AML)、肺腺癌和前列腺腺癌时应考虑其不良反应。相比之下,本文分析的Treg分子标记FoxP3和CD25在几乎所有癌症中都比正常人表达更强。然而,与FoxP3抑制剂相比,CD25抑制剂在预测患者生存方面更有效,尤其是在联合TGF-β阻滞剂时。根据癌症基因组图谱获得的数据,我们聚焦AML免疫治疗,讨论不同的治疗策略,包括抗CD25/IL-2、抗CTLA-4、抗IDO、抗酪氨酸激酶受体、抗PI3K治疗,并重点介绍AML免疫治疗的最新进展和临床成果。为了预测关键靶标抑制剂(即CTLA-4、FoxP3、CD25和PD-1)的风险和副作用,我们最终分析并比较了来自10种常见癌症的癌症基因组图谱。本综述显示Treg细胞在AML中显著增加,关键标志物的比较综述表明,Treg免疫治疗并不是对所有类型的癌症都有效。因此,AML中阻滞CD25(+)FoxP3(+) Treg细胞的提示多于其他类型的癌症;同时,在其他癌症中研究的Treg标记也为AML免疫治疗提供了很好的借鉴。
关键词: 调节性T细胞,肿瘤微环境,癌症免疫治疗,CD25
[http://dx.doi.org/10.1186/1479-5876-12-125] [PMID: 24886492]
[PMID: 7636184]
[http://dx.doi.org/10.3109/08916931003782155] [PMID: 21091291]
[http://dx.doi.org/10.1002/art.38761] [PMID: 24980778]
[http://dx.doi.org/10.1038/s41598-017-01788-z] [PMID: 28487507]
[http://dx.doi.org/10.1111/cas.14069] [PMID: 31102428]
[http://dx.doi.org/10.1093/biolre/ioy251] [PMID: 30496353]
[http://dx.doi.org/10.1038/nri.2016.26] [PMID: 27026074]
[http://dx.doi.org/10.4049/jimmunol.1701188] [PMID: 29311383]
[http://dx.doi.org/10.3389/fimmu.2014.00017] [PMID: 24478778]
[http://dx.doi.org/10.1007/s00281-018-0703-z] [PMID: 30187086]
[PMID: 29763402]
[http://dx.doi.org/10.1111/cei.13297] [PMID: 30913302]
[http://dx.doi.org/10.1517/14712598.2015.1000298] [PMID: 25553913]
[http://dx.doi.org/10.3389/fimmu.2016.00334] [PMID: 27656181]
[http://dx.doi.org/10.3389/fimmu.2018.00444] [PMID: 29593717]
[http://dx.doi.org/10.1016/j.bulcan.2018.07.005] [PMID: 30244981]
[http://dx.doi.org/10.1038/bcj.2016.50] [PMID: 27367478]
[http://dx.doi.org/10.1111/j.1365-3083.2009.02308.x] [PMID: 19751267]
[http://dx.doi.org/10.1002/iid3.136] [PMID: 28250921]
[http://dx.doi.org/10.1016/j.intimp.2018.08.034] [PMID: 30173051]
[http://dx.doi.org/10.31557/APJCP.2018.19.11.3019] [PMID: 30484986]
[http://dx.doi.org/10.1080/2162402X.2018.1433520] [PMID: 29872566]
[http://dx.doi.org/10.1038/nm1093] [PMID: 15322536]
[http://dx.doi.org/10.1158/2326-6066.CIR-18-0066] [PMID: 30068755]
[PMID: 10397255]
[http://dx.doi.org/10.1172/JCI25947] [PMID: 16308572]
[http://dx.doi.org/10.1002/eji.200939513] [PMID: 20127675]
[http://dx.doi.org/10.1016/j.ebiom.2018.12.015] [PMID: 30579870]
[http://dx.doi.org/10.1172/JCI31202] [PMID: 17476346]
[http://dx.doi.org/10.1038/nri1806] [PMID: 16557261]
[http://dx.doi.org/10.1371/journal.pone.0216893] [PMID: 31120919]
[http://dx.doi.org/10.1016/j.semcancer.2019.01.006] [PMID: 30716481]
[http://dx.doi.org/10.1200/JCO.2016.71.6795] [PMID: 28375787]
[http://dx.doi.org/10.1056/NEJMoa1003466] [PMID: 20525992]
[http://dx.doi.org/10.1126/science.271.5256.1734] [PMID: 8596936]
[http://dx.doi.org/10.1038/ni759] [PMID: 11812990]
[http://dx.doi.org/10.1016/S1074-7613(02)00280-7] [PMID: 11869690]
[http://dx.doi.org/10.1158/1078-0432.CCR-19-0289] [PMID: 31358539]
[http://dx.doi.org/10.1002/ijc.32181] [PMID: 30719701]
[http://dx.doi.org/10.1007/s12022-018-9557-0] [PMID: 30443770]
[http://dx.doi.org/10.3390/ijms20153676] [PMID: 31357555]
[http://dx.doi.org/10.18632/oncotarget.13972] [PMID: 28002796]
[http://dx.doi.org/10.1186/s12967-016-1037-z] [PMID: 27687804]
[http://dx.doi.org/10.1684/bdc.2010.1294] [PMID: 21339097]
[http://dx.doi.org/10.3389/fimmu.2019.00698] [PMID: 31024543]
[http://dx.doi.org/10.3390/ijms19123837] [PMID: 30513816]
[http://dx.doi.org/10.1084/jem.20062512] [PMID: 17502665]
[http://dx.doi.org/10.4161/onci.20387] [PMID: 22934258]
[http://dx.doi.org/10.1002/cyto.a.22117] [PMID: 22949266]
[http://dx.doi.org/10.1074/jbc.M109.047423] [PMID: 19858205]
[http://dx.doi.org/10.1172/jci.insight.95692] [PMID: 29212947]
[http://dx.doi.org/10.1080/2162402X.2017.1338239] [PMID: 28920002]
[http://dx.doi.org/10.1038/nm.3432] [PMID: 24362934]
[http://dx.doi.org/10.4049/jimmunol.1601231] [PMID: 28855309]
[http://dx.doi.org/10.1038/mi.2016.105] [PMID: 27924822]
[http://dx.doi.org/10.1038/nature05970] [PMID: 17581588]
[http://dx.doi.org/10.1016/j.celrep.2017.10.114] [PMID: 29166616]
[http://dx.doi.org/10.1016/j.bcp.2018.04.006] [PMID: 29656117]
[http://dx.doi.org/10.1016/j.trecan.2017.06.005] [PMID: 28780935]
[http://dx.doi.org/10.3390/vaccines4030028] [PMID: 27509527]
[http://dx.doi.org/10.4067/S0034-98872017000400001] [PMID: 28748988]
[http://dx.doi.org/10.1182/asheducation-2017.1.618] [PMID: 29222312]
[http://dx.doi.org/10.1371/journal.pone.0209295] [PMID: 30550585]
[http://dx.doi.org/10.1097/TP.0000000000002495] [PMID: 30451741]
[http://dx.doi.org/10.1182/blood-2014-01-551234] [PMID: 25006129]
[http://dx.doi.org/10.1111/bjh.12109] [PMID: 23116454]
[http://dx.doi.org/10.1186/s12967-019-1926-z] [PMID: 31171000]
[http://dx.doi.org/10.1080/10428194.2017.1410888] [PMID: 29251166]
[http://dx.doi.org/10.5045/br.2018.53.4.294] [PMID: 30588466]
[http://dx.doi.org/10.1152/ajpheart.00532.2007] [PMID: 17933973]
[http://dx.doi.org/10.3389/fimmu.2018.02407] [PMID: 30425709]
[http://dx.doi.org/10.1016/j.pharep.2018.07.005] [PMID: 30343043]
[http://dx.doi.org/10.1111/aji.13081] [PMID: 30589483]
[http://dx.doi.org/10.18632/oncotarget.2357] [PMID: 25327557]
[http://dx.doi.org/10.1016/j.bbrc.2014.06.141] [PMID: 25044110]
[http://dx.doi.org/10.1016/j.canlet.2018.01.017] [PMID: 29337110]
[http://dx.doi.org/10.1016/j.bbrc.2018.07.021] [PMID: 30007439]
[http://dx.doi.org/10.1016/j.bbrc.2019.05.040] [PMID: 31084930]
[http://dx.doi.org/10.4049/jimmunol.1701703] [PMID: 30692213]
[http://dx.doi.org/10.3389/fimmu.2018.02227] [PMID: 30319662]
[http://dx.doi.org/10.1158/1078-0432.CCR-08-3010] [PMID: 19417016]
[http://dx.doi.org/10.1182/blood-2018-03-838946] [PMID: 30425048]
[http://dx.doi.org/10.1172/jci.insight.120631] [PMID: 29875321]
[http://dx.doi.org/10.1007/s00262-017-2040-9] [PMID: 28721449]
[http://dx.doi.org/10.1007/s00262-009-0679-6] [PMID: 19283381]
[http://dx.doi.org/10.1016/j.leukres.2009.01.007] [PMID: 19233469]
[http://dx.doi.org/10.1182/blood-2006-07-036863] [PMID: 17164341]
[http://dx.doi.org/10.1158/2326-6066.CIR-16-0237] [PMID: 28246107]
[http://dx.doi.org/10.1038/s41422-018-0012-z] [PMID: 29463898]
[http://dx.doi.org/10.1097/CJI.0000000000000277] [PMID: 31145230]
[http://dx.doi.org/10.1038/s41591-019-0420-8] [PMID: 31036879]
[http://dx.doi.org/10.1001/jamaoncol.2018.3923] [PMID: 30242316]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035898] [PMID: 30359135]
[http://dx.doi.org/10.1634/theoncologist.2018-0359] [PMID: 30482825]
[http://dx.doi.org/10.2337/dc18-1465] [PMID: 30305348]
[http://dx.doi.org/10.1016/j.clim.2014.09.012] [PMID: 25267440]
[http://dx.doi.org/10.1073/pnas.1820388116] [PMID: 30760587]
[http://dx.doi.org/10.1186/s12967-018-1673-6] [PMID: 30359281]
[http://dx.doi.org/10.5114/ceji.2018.77381] [PMID: 30135623]
[http://dx.doi.org/10.1002/jcb.26210] [PMID: 28608558]
[http://dx.doi.org/10.1159/000446989] [PMID: 27303788]
[http://dx.doi.org/10.1016/j.pharmthera.2018.04.009] [PMID: 29698683]
[http://dx.doi.org/10.1371/journal.pone.0143435] [PMID: 26579709]
[http://dx.doi.org/10.1038/s41379-018-0061-3] [PMID: 29802358]
[http://dx.doi.org/10.1016/j.cellimm.2018.07.011] [PMID: 30093071]
[http://dx.doi.org/10.1097/MD.0000000000015424] [PMID: 31096438]
[http://dx.doi.org/10.1016/j.ejphar.2017.08.011] [PMID: 28811127]
[PMID: 31168192]
[http://dx.doi.org/10.1016/j.critrevonc.2019.03.007] [PMID: 31014507]
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2468] [PMID: 25524312]
[http://dx.doi.org/10.1182/blood-2014-05-570291] [PMID: 24948620]
[http://dx.doi.org/10.3389/fimmu.2018.01274] [PMID: 29922294]
[http://dx.doi.org/10.7150/thno.14394] [PMID: 27162549]
[http://dx.doi.org/10.1080/1744666X.2017.1245146] [PMID: 27782752]
[http://dx.doi.org/10.1038/s41467-017-01570-9] [PMID: 29176694]
[http://dx.doi.org/10.1158/2159-8290.CD-17-0226] [PMID: 28630051]
[http://dx.doi.org/10.1016/j.semcancer.2017.02.010] [PMID: 28257957]
[http://dx.doi.org/10.1016/j.cell.2018.09.035] [PMID: 30290139]